TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03796455

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsule + Powder supplementation
Description: For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsule + Powder supplementation
Description: For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsule + Powder supplementation
Description: For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable tracer infusion
Description: labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable tracer infusion
Description: labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: stable tracer infusion
Description: labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day
Study: NCT00874627

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Milk
Description: placebo
Study: NCT01551550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GDD
Description: The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GDD
Description: The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Graft
Description: For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericardial Graft
Description: For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
Study: NCT02947932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: pre-ERCP intervention
Study: NCT04240418

Intervention type: OTHER
Intervention: Survey
Description: The objective is to evaluate the eligibility of the responders, as defined by NELSON criteria and PLCOm2012 scoring, and their willingness to participate to a lung-cancer screening with low-dose computed tomography.
Study: NCT04174170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Up to 3 mg pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Up to 150 mg pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Up to 150 mg pill

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill
Study: NCT02947932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: post-ERCP intervention in high risk patients
Study: NCT00987467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin 0.05% ophthalmic
Description: Cyclosporine 0.05% ophthalmic solution, 1 drop 6 times in both eyes daily for first month, then 1 drop 4 times in both eyes daily for next month, then dosage was adjusted based on clinical disease by investigator.
Study: NCT04174170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pill
Study: NCT00410566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhASM
Description: Single dose of 0.03mg/kg body weight IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhASM
Description: Single dose of 0.1mg/kg body weight IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhASM
Description: Single dose of 0.3mg/kg body weight IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhASM
Description: Single dose of 0.6mg/kg body weight IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhASM
Description: Single dose of 1.0mg/kg body weight IV
Study: NCT01361399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain
Description: Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Single oral application of Aspirin (as lozenge)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain
Description: Single oral application of Lidocain (as lozenge)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral application of Placebo (as lozenge)
Study: NCT00988234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SGPP
Description: ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SGTPP
Description: ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SGLP
Description: ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SGTLP
Description: ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
Study: NCT04193059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80 mg/m\^2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80 mg/m\^2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: epirubicin 90 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: epirubicin 90 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle, 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle, 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy; or trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy; or trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant pertuzumab (420mg ivgtt every 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant pertuzumab (420mg ivgtt every 3 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel 100 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel 100 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
Study: NCT02109926

Intervention type: OTHER
Intervention: Phone interview and blood test
Description: Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms

Intervention type: OTHER
Intervention: Phone interview and blood test
Description: Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms

Intervention type: OTHER
Intervention: Phone interview and blood test
Description: Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
Study: NCT05886699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP combined with DFDBA
Description: Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DFDBA
Description: Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
Study: NCT03010085

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open left-sided hepatectomy
Description: Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic left-sided hepatectomy
Description: Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
Study: NCT01331785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
Study: NCT04478071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat
Description: Participants will receive vadadustat once daily for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive matching placebo once daily for 14 days.
Study: NCT01677910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate tablets.
Study: NCT03912259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: solution,~Route of administration: SC
Study: NCT01677910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching telotristat etiprate
Description: Placebo-matching telotristat etiprate tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching telotristat etiprate
Description: Placebo-matching telotristat etiprate tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching telotristat etiprate
Description: Placebo-matching telotristat etiprate tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching telotristat etiprate
Description: Placebo-matching telotristat etiprate tablets.
Study: NCT02909725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limit accumulation of sedentary time
Description: Participants in this group receive a Fitbit Alta activity monitor, worn on the wrist for the entire intervention. The Alta is a fitness tracker designed to help individuals track their sedentary and physical activity behaviors when paired with an external device (e.g. iPhone, computer). The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to achieve a goal of 250 steps/hour. Using the reminder to move function, if a participant has not reached the hourly goal at 50 minutes, the Alta will vibrate, cueing the participant to walk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk
Description: Participants in this group receive a Fitbit Charge activity monitor. There is no reminder to move function on this band. The Charge, worn on the wrist for the entire intervention is a fitness tracker designed to help individuals track their physical activity when paired with an external device. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to meet current pregnancy physical activity recommendations; walking 30 minutes, most days of the week (150 minutes/week). Participants can use the app to view their active minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal daily routine; Usual Care
Description: Participants in this group will not be provided with a Fitbit Charge activity monitor, as participants will be asked to simply continue on with their normal daily routine. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
Study: NCT00580983

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Study: NCT02775253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic cold acclimation
Study: NCT04274192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synchronized HFNC at 6 liters per minute (LPM)
Description: HFNC given in synchrony with the subject's own respiratory effort using NAVA at 6 LPM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronized HFNC at 6 liters per minute (LPM)
Description: HFNC given in synchrony with the subject's own respiratory effort using NAVA at 6 LPM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous HFNC at 6 liters per minute (LPM)
Description: Standard HFNC therapy at 6 LPM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous HFNC at 6 liters per minute (LPM)
Description: Standard HFNC therapy at 6 LPM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synchronized HFNC at 8 liters per minute (LPM)
Description: HFNC given in synchrony with the subject's own respiratory effort using NAVA at 8 LPM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronized HFNC at 8 liters per minute (LPM)
Description: HFNC given in synchrony with the subject's own respiratory effort using NAVA at 8 LPM
Study: NCT01061775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
Study: NCT04274192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous HFNC at 8 liters per minute (LPM)
Description: Standard HFNC therapy at 8 LPM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous HFNC at 8 liters per minute (LPM)
Description: Standard HFNC therapy at 8 LPM
Study: NCT00203502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV 15mg/kg 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg per meter squared, IV every 21 days
Study: NCT02658682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Computer based Attention Bias Modification

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Attention Bias Modification
Description: Computer based Sham Attention Bias Modification
Study: NCT01814579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unidirectional Barbed Suture (V-Loc)
Description: Patients enrolled in the Unidirectional Barbed Suture arm will have their vaginal cuff closed using this device during their robotic hysterectomy.
Study: NCT03912259

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution,~Route of administration: SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emollient (moisturizer)
Description: Pharmaceutical form: cream,~Route of administration: topical use
Study: NCT00203502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg per meter squared, IV every 21 days
Study: NCT00597779

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)
Description: Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)
Description: Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
Study: NCT03912259

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Emollient (moisturizer)
Description: Pharmaceutical form: cream,~Route of administration: topical use
Study: NCT00791024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRC-Pharma 001
Description: 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine suspension
Description: 5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
Study: NCT01814579

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polyglactin 910 (Vicryl)
Description: Patients in the Smooth Suture arm will have their vaginal cuff closed with this device during their robotic hysterectomy.
Study: NCT00826631

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast food arm
Description: Doubling of regular caloric intake based on fast food, no exercise allowed
Study: NCT03955666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-3279 or placebo
Description: bi-specific antibody-based molecule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-3279 or placebo
Description: bi-specific antibody-based molecule
Study: NCT04166981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumented posterolateral spine fusion.
Description: Posterolateral fusion with autologous and allogenic bone graft with supplementary pedicle screw fixation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-instrumented posterolateral spine fusion.
Description: Posterolateral fusion with autologous and allogenic bone graft.
Study: NCT03855319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMR neurofeedback training to MCI
Description: The intervention consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta training was recorded at channel Cz according to the international 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed.A 32 channels system (EEGDigitrcak Biofeedback plus module, Inc Elmiko Medical) was used for the SMR/theta Neurofeedback training.
Study: NCT01525706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol and Paclitaxel Injection
Description: Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL \[3mg/ml diluted in normal saline from original concentration of 6mg/mL\] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
Study: NCT04262310

Intervention type: OTHER
Intervention: Small Bowel and Colonic Permeability Test
Description: small bowel and colonic permeability based on oral probe molecules and urine excretion in 60 healthy white, female and male adults aged 18-70y
Study: NCT02100865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solar powered oxygen
Study: NCT03179228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate Embolization
Description: Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin